If you or someone you know has developed uncontrollable facial or body movements after taking Reglan, you may be concerned about tardive dyskinesia. Medical research has long established that prolonged use of metoclopramide increases the risk of this movement disorder. This page reviews the key risk factors reported in the scientific literature, helping you understand who may be most vulnerable.
Reglan (metoclopramide) is a prescription medication approved for short-term treatment of symptomatic gastroesophageal reflux in adults and for relief of symptoms in adults with acute and recurrent diabetic gastroparesis. The FDA-approved labeling explicitly states that Reglan has not been shown to be safe and effective for gastroesophageal reflux for longer than 12 weeks, and that Reglan tablets are not recommended for use in pediatric patients due to the risk of tardive dyskinesia (TD) and other extrapyramidal symptoms (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Despite these limitations, many patients have been prescribed Reglan for extended periods, sometimes for months or years, increasing their risk of developing TD.
Tardive dyskinesia is a syndrome of potentially irreversible and disfiguring involuntary movements of the face or tongue, and sometimes of the trunk and/or extremities (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The condition can manifest as repetitive, purposeless movements such as lip smacking, tongue protrusion, grimacing, and rapid blinking. In more severe cases, it may involve choreiform movements of the limbs or trunk. The clinical presentation can vary widely, and the severity may range from mild, barely noticeable movements to disabling dyskinesias that interfere with daily activities. Diagnosis is typically based on a thorough clinical evaluation, including a detailed history of medication exposure and a neurological examination. There is no definitive diagnostic test for TD; instead, clinicians rely on the presence of characteristic involuntary movements in a patient with a history of exposure to dopamine-blocking agents like metoclopramide. The mechanistic pathway linking Reglan to TD involves the drug's action as a dopamine D2 receptor antagonist in the central nervous system. Metoclopramide blocks dopamine receptors in the striatum, a region of the brain involved in motor control. Chronic blockade of these receptors is thought to lead to upregulation and supersensitivity of dopamine receptors, resulting in an imbalance between dopamine and other neurotransmitters. This imbalance is believed to underlie the development of involuntary movements characteristic of TD. The risk of developing TD increases with duration of treatment and total cumulative dosage (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The FDA boxed warning emphasizes that metoclopramide, including Reglan, can cause TD, a potentially irreversible serious movement disorder, and that the risk increases with longer treatment duration and higher cumulative doses (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397).
The adequacy of warnings regarding Reglan and TD has been a subject of legal scrutiny. The FDA-approved labeling includes a boxed warning that clearly states the risk of TD, the need to use Reglan for the shortest duration possible, and the importance of periodically reassessing the need for continued treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The labeling also notes that Reglan is contraindicated in patients with a history of TD and that treatment should be immediately discontinued if signs or symptoms of TD develop (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). However, critics argue that these warnings were not sufficiently emphasized in earlier versions of the label or in direct-to-consumer marketing, and that many prescribers and patients were unaware of the significant risk of TD with long-term use. The adequacy of warnings is a key factor in determining liability in product liability lawsuits. Settlement-related considerations for affected patients in Massachusetts involve several factors. First, the statute of limitations for filing a personal injury lawsuit in Massachusetts is generally three years from the date the injury is discovered or reasonably should have been discovered. For TD, this means the clock starts ticking when the patient first becomes aware of the involuntary movements and their potential link to Reglan. Given that TD can develop insidiously over months or years, determining the exact date of discovery can be complex. Patients who have been diagnosed with TD after long-term Reglan use should consult with an attorney promptly to assess their legal options. Settlement amounts in Reglan TD cases have varied widely, depending on factors such as the severity of the TD, the duration of Reglan use, the strength of the evidence linking the TD to Reglan, and the specific facts of the case. Some settlements have been reached for substantial sums, particularly in cases where the patient developed severe, disabling TD after prolonged use of Reglan without adequate warnings.
The timeline between exposure to Reglan and documented harm is critical in both clinical and legal contexts. TD typically does not appear immediately after starting Reglan; it often develops after months or years of continuous use. The FDA boxed warning states that the risk increases with duration of treatment and total cumulative dosage (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). In some cases, TD may become apparent only after Reglan is discontinued, as the drug can partially suppress the signs of TD and delay diagnosis (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). This masking effect can make it difficult for patients and clinicians to recognize the condition early. Once TD is diagnosed, the movements may be irreversible, even after Reglan is stopped. The FDA recommends that Reglan be used for the shortest duration of treatment and that the need for continued treatment be periodically reassessed (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). For patients with diabetic gastroparesis, the labeling advises avoiding a total duration of treatment longer than 12 weeks, and if longer-term use is unavoidable, to routinely monitor for signs and symptoms of TD (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397).
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
In Massachusetts, the statute of limitations for personal injury lawsuits is generally three years from the date the injury is discovered or reasonably should have been discovered. For tardive dyskinesia caused by Reglan, this means the clock starts when the patient becomes aware of the involuntary movements and their potential link to the drug. Given the insidious onset of TD, it is crucial to consult an attorney promptly after diagnosis.
Yes, you may still be able to file a claim if the diagnosis occurred within the statute of limitations period. The discovery rule in Massachusetts allows the limitations period to begin when the injury is discovered or reasonably should have been discovered. However, delays in diagnosis can complicate the timeline, so it is important to seek legal advice as soon as possible.
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.